Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAMMER I: Liver SBRT + Ipilimumab/Nivolumab in Melanoma
NCT05169957Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percentage of patients who receive all planned radiotherapy. Started Aug 2022; status: completed.
Beyond the preview
Go deeper on NCT05169957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169957.